Are you Dr. Rarick?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 49 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
3600 N Interstate Ave
Portland, OR 97227Phone+1 503-285-9321Fax+1 503-331-6505
Summary
- Dr. Mark Rarick, MD is an oncologist in Portland, Oregon. He is currently licensed to practice medicine in Oregon, Washington, and California. He is affiliated with Kaiser Sunnyside Medical Center.
Education & Training
University of Southern California/LAC+USC Medical CenterFellowship, Hematology, 1983 - 1985
Ohio State University HospitalResidency, Internal Medicine, 1980 - 1983
Keck School of Medicine of the University of Southern CaliforniaClass of 1980
Certifications & Licensure
CA State Medical License 1983 - Present
OR State Medical License 1991 - 2025
WA State Medical License 1997 - 2016
OH State Medical License 1981 - 1984- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Clinical Trials
- Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma Start of enrollment: 2010 Jun 22
- Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Start of enrollment: 2013 Jul 12
Publications & Presentations
PubMed
- 17 citationsA phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metast...B H O'Neil, A J Scott, W W Ma, S J Cohen, D L Aisner
Annals of Oncology. 2015-09-01 - 137 citationsRandomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic CancerMitesh J. Borad, Shantan G. Reddy, Nathan Bahary, Hope E. Uronis, Darren Sigal
Journal of Clinical Oncology. 2015-05-01 - 118 citationsA randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small cell lung cancerAlberto Chiappori, Tatjana Kolevska, David R. Spigel, Steven Hager, Mark U. Rarick
Annals of Oncology. 2015-02-01
Professional Memberships
- Member
